ZBIOZenas BioPharma, Inc.
Price
+44%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Nothing alarming, growth fading, the market undecided.
We are a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving understanding of the pathogenesis of autoimmune diseases, along with the expansion of promising immunology-based pharmacologic targets, we are building an I&I focused biopharmaceutical company. Our core business strategy combines disciplined product candidate acquisition with strategic deployment of internal expertise and effective use of external resources.
In the company’s own words · 10-K filed Mar 16, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Zenas BioPharma, Inc. (ZBIO) reported revenue of $1.0M in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $111M. For the full year FY2025, revenue was $10M (+100% year on year) and net income −$378M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026Appointment of Christy J. Oliger Upon the recommendation of the Nominating and Corporate Governance Committee of the Company’s Board of Directors (the “Board”), on August 12, 2026, the Board appointed Christy J. Oliger to serve on the Board as a Class II director to hold office until the Company’s annual meeting of …Earnings release · Form 8-K
- May 13, 2026On May 11, 2026, Zenas BioPharma, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Earnings release · Form 8-K
- Mar 31, 2026On March 31, 2026, Zenas BioPharma, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $200,000,000 aggregate principal amount of its 2.50% Convertible Senior Notes due 2032 (the “Notes”)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry